bluebird bio (BLUE) has risen sharply, recording gains of 23.95% in the past 4 weeks. However, the stock has corrected -1.73% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 22.68% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 7.57% and the 50-Day Moving Average is 19.73%. bluebird bio (NASDAQ:BLUE): stock turned positive on Friday. Though the stock opened at $55.49, the bulls momentum made the stock top out at $57.06 level for the day. The stock recorded a low of $54.95 and closed the trading day at $56.8, in the green by 2.38%. The total traded volume for the day was 531,279. The stock had closed at $55.48 in the previous days trading.
The company Insiders own 3.5% of bluebird bio shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -14.9% . During last six month period, the net percent change held by insiders has seen a change of -14.9%. Also, Cantor Fitzgerald initiates coverage on bluebird bio (NASDAQ:BLUE) The current rating of the shares is Hold. Equity Analysts at the Firm announces the price target to $42 per share. The rating by the firm was issued on June 2, 2016.
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Companys products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.